<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881892</url>
  </required_header>
  <id_info>
    <org_study_id>041/57</org_study_id>
    <nct_id>NCT02881892</nct_id>
  </id_info>
  <brief_title>Iplasma IL6, Procalcitonin and VEGF and Dialysate Level in CAPD Patients</brief_title>
  <official_title>Interleukin-6, Procalcitonin and Vascular Endothelial Growth Factor in Plasma and Dialysate Correlate With Peritoneal Solute Transport and Dialysis Adequacy in CAPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangkok Metropolitan Administration Medical College and Vajira Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangkok Metropolitan Administration Medical College and Vajira Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study was to evaluated the correlation between plasma levels, dialysate appearance
      rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in
      CAPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cross -sectional study measured IL-6, procalcitonin and VEGF level in plasma and
      overnight effluent. PSTR of small solutes was evaluated by standard peritoneal equilibration
      test (standard PET). Weekly Kt/V and creatinine clearance (CCr ) were evaluated in all
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>plasma level of VEGF, IL-6 and procalcitonin with the PSTR and dialysis adequacy in CAPD patients</measure>
    <time_frame>2 years</time_frame>
    <description>measure in pg/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokines in diabetic and non-diabetic group</measure>
    <time_frame>2 years</time_frame>
    <description>All cytokines in plasma and blood</description>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measure plasma and dialysate level of IL-6, procalcitonin and VEGF</intervention_name>
    <description>correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CAPD patients age more than 18 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable CAPD patients without previous history of peritonitis

        Exclusion Criteria:

          -  HIV

          -  Other infections, tuberculosis or on immunosuppressive drugs,

          -  Autoimmune disease,

          -  Cancer

          -  Diagnosis of permanent ultrafiltration failure .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thananda Trakarnvniach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine,Vajira Hospital,Navamindradhiraj University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renal Unit, BMA Medical College and Vajira Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Oh KH, Jung JY, Yoon MO, Song A, Lee H, Ro H, Hwang YH, Kim DK, Margetts P, Ahn C. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant. 2010 May;25(5):1639-46. doi: 10.1093/ndt/gfp670. Epub 2010 Jan 8.</citation>
    <PMID>20061317</PMID>
  </reference>
  <reference>
    <citation>Alscher DM, Mettang T. Procalcitonin in peritoneal dialysis--a useful marker of inflammation? Perit Dial Int. 2005 Sep-Oct;25(5):441-4.</citation>
    <PMID>16178476</PMID>
  </reference>
  <reference>
    <citation>Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005 Feb;61(2):180-6.</citation>
    <PMID>15683455</PMID>
  </reference>
  <reference>
    <citation>Guz G, Colak B, Hizel K, Reis KA, Erten Y, Bali M, Sindel S. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int. 2006 Mar-Apr;26(2):240-8.</citation>
    <PMID>16623432</PMID>
  </reference>
  <results_reference>
    <citation>Pecoits-Filho R, Araújo MR, Lindholm B, Stenvinkel P, Abensur H, Romão JE Jr, Marcondes M, De Oliveira AH, Noronha IL. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant. 2002 Aug;17(8):1480-6.</citation>
    <PMID>12147798</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangkok Metropolitan Administration Medical College and Vajira Hospital</investigator_affiliation>
    <investigator_full_name>Thananda Trakarnvanich</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>CAPD</keyword>
  <keyword>Peritoneal solute transport rate</keyword>
  <keyword>Dialysis adequacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

